Answers are grounded in this paper and cite their sources.
N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid (15), prepared in five steps from 2-pivaloyl-7-deazaguanine, has been found to be an antitumor agent with its primary site of action at thymidylate synthase rather than purine synthesis. This compound appears to be a promising candidate for clinical evaluation.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: